Analyst Coverage
Stock price graph

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective.

Recent Releases

Feb 2, 2017
Repros Announces New CEO

Jan 30, 2017
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids

View all releases »

2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3446 fax